Health and Me

Rachel V Thomas

Lung Cancer: 2 Drugs From GSK, BioNTech Show Improved Survival, 94% Response

Lung Cancer: 2 GSK, BioNTech Drugs Show Survival, 94% Response

<a href="https://www.healthandme.com/health/lung-cancer">Lung cancer</a> is the leading cause of cancer cases and deaths worldwide, with an estimated 2.5 million new cases and 1.8 million deaths in 2022.

Lung cancer is often diagnosed at later stages, when five-year survival rates are lowest. Now, two drugs developed by pharma giants GSK and BioNTech have shown promising results in major clinical trials.

Data presented at the ongoing International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, showed that the drugs could improve survival and produce high tumour response rates in patients with certain types of non-small cell lung cancer (NSCLC).

GSK's Jideytro Shows 94% Response Rate

GSK announced positive results from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in patients with ROS1-positive NSCLC who had not previously received treatment with a tyrosine kinase inhibitor.

Among patients who had not previously received a tyrosine kinase inhibitor (TKI), an oral targeted therapy, Jideytro triggered an objective response in 88 patients, giving an objective response rate of 94%.

These patients were allowed to have received up to one prior line of chemotherapy, with or without immunotherapy, before entering the study.

GSK reported that 90% of patients remained progression-free at 12 months. Notably, 70% of patients with brain metastases saw complete clearance of detectable tumors.

With the promising results, the company said it will apply for a supplemental New Drug Application to the US Food and Drug Administration later this year to expand Jideytro's approval into first-line use.

Jideytro was already approved in July 2026 for previously treated patients with advanced ROS1-positive NSCLC.

<h2>BioNTech Drug Nearly Doubles Survival</h2>

German biopharmaceutical company BioNTech said its experimental immunotherapy gotistobart (BNT316/ONC-392) produced a significant overall-survival benefit in the Phase 3 PRESERVE-003 trial in previously treated metastatic squamous NSCLC.

Gotistobart is an investigational immunomodulator that targets CTLA-4 and is designed to selectively enhance regulatory T-cell depletion in the tumor microenvironment.

According to the company, median overall survival was 18.5 months with gotistobart, compared with 10.0 months with standard-of-care docetaxel chemotherapy, nearly doubling median survival in this patient population.

The findings suggest potential for gotistobart as a chemotherapy-free treatment approach in previously treated patients with squamous NSCLC.

“The magnitude of the survival benefit observed with gotistobart as a chemotherapy-free treatment approach in the PRESERVE-003 clinical trial is highly encouraging. If confirmed in the pivotal portion of the Phase 3 trial, these findings could transform the standard of care in a setting where new therapies are urgently needed,” said Rama Balaraman, Principal Investigator and medical oncologist at Ocala Oncology Center, Florida, US.

Lung cancer is a serious disease and remains a major public health challenge worldwide due to its high incidence and mortality. 

Lung cancer occurs when abnormal cells grow uncontrollably in the lungs. Treatment depends on a person's medical history and the stage of the disease.

The two main types of lung cancer are non-small cell lung cancer (NSCLC), which accounts for around 85% of cases, and small cell lung cancer (SCLC), which is less common but typically more aggressive.

With a five-year relative survival rate of 15% and a median overall survival of 11 months in the United States between 2000 and 2017, squamous NSCLC is a devastating disease with limited treatment options.

Health Conditions A-Z

health

lung-cancer-2-gsk-biontech-drugs-show-survival-94-response

lung

lung cancer

nsclc

jideytro

gotistobart

us food and drug administration

us-measles-outbreak-can-vaccinated-people-still-get-infected

US Measles Outbreak: Can Vaccinated People Still Get Infected?

glutathione-iv-drips-are-trending-for-skin-brightening-are-they-safe

Glutathione IV Drips Are Trending For Skin Brightening: Are They Safe?

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Lung cancer is the leading cause of cancer cases and deaths worldwide, with an estimated 2.5 million new cases and 1.8 million deaths in 2022.Lung cancer is often diagnosed at later stages, when five-year survival rates are lowest. Now, two drugs developed by pharma giants GSK and BioNTech have shown promising results in major clinical trials.Data presented at the ongoing International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, showed that the drugs could improve survival and produce high tumour response rates in patients with certain types of non-small cell lung cancer (NSCLC).GSK's Jideytro Shows 94% Response RateGSK announced positive results from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in patients with ROS1-positive NSCLC who had not previously received treatment with a tyrosine kinase inhibitor.Among patients who had not previously received a tyrosine kinase inhibitor (TKI), an oral targeted therapy, Jideytro triggered an objective response in 88 patients, giving an objective response rate of 94%.These patients were allowed to have received up to one prior line of chemotherapy, with or without immunotherapy, before entering the study.GSK reported that 90% of patients remained progression-free at 12 months. Notably, 70% of patients with brain metastases saw complete clearance of detectable tumors.With the promising results, the company said it will apply for a supplemental New Drug Application to the US Food and Drug Administration later this year to expand Jideytro's approval into first-line use.Jideytro was already approved in July 2026 for previously treated patients with advanced ROS1-positive NSCLC.BioNTech Drug Nearly Doubles SurvivalGerman biopharmaceutical company BioNTech said its experimental immunotherapy gotistobart (BNT316/ONC-392) produced a significant overall-survival benefit in the Phase 3 PRESERVE-003 trial in previously treated metastatic squamous NSCLC.Gotistobart is an investigational immunomodulator that targets CTLA-4 and is designed to selectively enhance regulatory T-cell depletion in the tumor microenvironment.According to the company, median overall survival was 18.5 months with gotistobart, compared with 10.0 months with standard-of-care docetaxel chemotherapy, nearly doubling median survival in this patient population.The findings suggest potential for gotistobart as a chemotherapy-free treatment approach in previously treated patients with squamous NSCLC. “The magnitude of the survival benefit observed with gotistobart as a chemotherapy-free treatment approach in the PRESERVE-003 clinical trial is highly encouraging. If confirmed in the pivotal portion of the Phase 3 trial, these findings could transform the standard of care in a setting where new therapies are urgently needed,” said Rama Balaraman, Principal Investigator and medical oncologist at Ocala Oncology Center, Florida, US.What Is Lung Cancer?Lung cancer is a serious disease and remains a major public health challenge worldwide due to its high incidence and mortality. Lung cancer occurs when abnormal cells grow uncontrollably in the lungs. Treatment depends on a person's medical history and the stage of the disease.The two main types of lung cancer are non-small cell lung cancer (NSCLC), which accounts for around 85% of cases, and small cell lung cancer (SCLC), which is less common but typically more aggressive.With a five-year relative survival rate of 15% and a median overall survival of 11 months in the United States between 2000 and 2017, squamous NSCLC is a devastating disease with limited treatment options.

lung cancer: 2 gsk, biontech drugs show survival, 94% response

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Lung Cancer: 2 Drugs From GSK, BioNTech Show Improved Survival, 94% Response

US Measles Outbreak: Can Vaccinated People Still Get Infected?

More COVID Infections, More Health Problems? Back, Respiratory, Mental Problems Among New Risks

CDC Survey Shows Nearly 3 In 4 American Adults Are Tired: Who Is Most Affected?

Health Conditions A-Z